Header Logo

Connection

John Zajecka to Depressive Disorder

Back to Details
This is a "connection" page, showing publications John Zajecka has written about Depressive Disorder.
John Zajecka
Connection Strength
2.883
Depressive Disorder
  1. Treating depression to remission. J Clin Psychiatry. 2003; 64 Suppl 15:7-12.
    View in: PubMed
    Score: 0.193
  2. Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combination. J Clin Psychiatry. 2002 Aug; 63(8):709-16.
    View in: PubMed
    Score: 0.188
  3. Antidepressant dosing and switching guidelines: focus on nefazodone. J Clin Psychiatry. 2002; 63 Suppl 1:42-7.
    View in: PubMed
    Score: 0.180
  4. Strategies for the treatment of antidepressant-related sexual dysfunction. J Clin Psychiatry. 2001; 62 Suppl 3:35-43.
    View in: PubMed
    Score: 0.168
  5. Pharmacotherapy of depression and mixed states in bipolar disorder. J Affect Disord. 2000 Sep; 59 Suppl 1:S39-S56.
    View in: PubMed
    Score: 0.164
  6. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med. 2000 May 18; 342(20):1462-70.
    View in: PubMed
    Score: 0.161
  7. Clinical issues in long-term treatment with antidepressants. J Clin Psychiatry. 2000; 61 Suppl 2:20-5.
    View in: PubMed
    Score: 0.157
  8. Changes in adverse events reported by patients during 6 months of fluoxetine therapy. J Clin Psychiatry. 1999 Jun; 60(6):389-94.
    View in: PubMed
    Score: 0.151
  9. Safety of abrupt discontinuation of fluoxetine: a randomized, placebo-controlled study. J Clin Psychopharmacol. 1998 Jun; 18(3):193-7.
    View in: PubMed
    Score: 0.141
  10. Treatment-emergent changes in sexual function with selective serotonin reuptake inhibitors as measured with the Rush Sexual Inventory. Psychopharmacol Bull. 1997; 33(4):755-60.
    View in: PubMed
    Score: 0.127
  11. The effect of nefazodone on comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatient settings. J Clin Psychiatry. 1996; 57 Suppl 2:10-4.
    View in: PubMed
    Score: 0.119
  12. The efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant depression: a retrospective analysis. J Clin Psychiatry. 1995 Aug; 56(8):338-43.
    View in: PubMed
    Score: 0.115
  13. Management of comorbid anxiety and depression. J Clin Psychiatry. 1995; 56 Suppl 2:10-3.
    View in: PubMed
    Score: 0.111
  14. Divalproex sodium in the treatment of refractory affective disorders. J Clin Psychiatry. 1993 Oct; 54(10):380-4.
    View in: PubMed
    Score: 0.102
  15. Susceptibility to spontaneous MAOI hypertensive episodes. J Clin Psychiatry. 1991 Dec; 52(12):513-4.
    View in: PubMed
    Score: 0.090
  16. Antidepressant combination and potentiation. Psychiatr Med. 1991; 9(1):55-75.
    View in: PubMed
    Score: 0.084
  17. Innovative somatic treatments for depression. Psychiatr Med. 1991; 9(1):77-103.
    View in: PubMed
    Score: 0.084
  18. Coexisting major depression and obsessive-compulsive disorder treated with venlafaxine. J Clin Psychopharmacol. 1990 Apr; 10(2):152-3.
    View in: PubMed
    Score: 0.080
  19. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases. J Clin Psychiatry. 2007 Aug; 68(8):1246-56.
    View in: PubMed
    Score: 0.066
  20. Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder. Int Clin Psychopharmacol. 2003 May; 18(3):151-6.
    View in: PubMed
    Score: 0.049
  21. Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. J Clin Psychiatry. 2002 May; 63(5):434-41.
    View in: PubMed
    Score: 0.046
  22. Six-year perspectives on the safety and tolerability of nefazodone. J Clin Psychiatry. 2002; 63 Suppl 1:32-41.
    View in: PubMed
    Score: 0.045
  23. Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. J Clin Psychiatry. 2001 Jun; 62(6):413-20.
    View in: PubMed
    Score: 0.043
  24. Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders. Arch Gen Psychiatry. 2000 Jan; 57(1):76-82.
    View in: PubMed
    Score: 0.039
  25. Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry. 1999 Aug; 156(8):1170-6.
    View in: PubMed
    Score: 0.038
  26. Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. Am J Psychiatry. 1998 Sep; 155(9):1247-53.
    View in: PubMed
    Score: 0.036
  27. Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. Discontinuation Consensus panel. J Clin Psychiatry. 1997; 58 Suppl 7:5-10.
    View in: PubMed
    Score: 0.032
  28. Clinical management of antidepressant discontinuation. J Clin Psychiatry. 1997; 58 Suppl 7:37-40.
    View in: PubMed
    Score: 0.032
  29. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. J Clin Psychopharmacol. 1991 Apr; 11(2):127-32.
    View in: PubMed
    Score: 0.021
  30. The role of serotonin in sexual dysfunction: fluoxetine-associated orgasm dysfunction. J Clin Psychiatry. 1991 Feb; 52(2):66-8.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.